Table 2.
Baseline demographics and clinical characteristics of the study population
| HD n=21 | ICI n=5 | TKI n=17 | Anti-CD20 n=9 | Antibody n=24 | Cht-ICI n=27 | Chemo n=72 | Cortisone n=101 | |
| Age | 59.6 (39–81) | 68 (39–86) | 69 (62–80) | 66 (39–86) | 66 (39–86) | 63 (34–86) | 64 (37–86) | |
| Sex | ||||||||
| Male Female |
7 (33%) 14 (67%) |
1 (20%) 4 (80%) |
9 (53%) 8 (47%) |
7 (78%) 2 (22%) |
14 (37%) 24 (63%) |
8 (30%) 19 (70%) |
23 (32%) 49 (68%) |
33 (33%) 68 (67%) |
| Therapy time point* | ||||||||
| Active Intermediate Late Not active |
4 / / 1 |
9 2 1 5 |
/ 2 2 5 |
8 3 4 9 |
13 2 2 10 |
8 2 1 14 |
20 28 10 41 |
Data are mean (SD) or n (%).
*Participants receiving systemic cancer therapy previous to vaccination were subdivided into active (last therapy up to 4 weeks before blood donation), intermediate (last therapy more than 4 weeks before blood donation but less than 6 months), late (last therapy 6–12 months before blood donation) and non-active therapies (last therapy more than 12 months before blood donation).
HD, healthy donor; ICI, immune checkpoint inhibitor; TKI, tyrosine kinase inhibitors.